Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity

被引:48
作者
Ryabtsova, Oxana [1 ]
Jansen, Koen [1 ]
Van Goethem, Sebastiaan [1 ]
Joossens, Jurgen [1 ]
Cheng, Jonathan D. [2 ]
Lambeir, Anne-Marie
De Meester, Ingrid
Augustyns, Koen [1 ]
Van der Veken, Pieter [1 ]
机构
[1] Univ Antwerp UA, Dept Pharmaceut Sci, Med Chem UAMC, B-2610 Antwerp, Belgium
[2] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
关键词
Fibroblast activation protein-alpha; FAP; Seprase; DPP IV; DPP4; PREP; Prolyl oligopeptidase; Val-boroPro; PT-100; Talabostat; DIPEPTIDYL-PEPTIDASE; SERINE-PROTEASE; POTENT; ENZYME; IV; ISOINDOLINE; SPECIFICITY; ANTIBODY; COLLAGEN; CELLS;
D O I
10.1016/j.bmcl.2012.03.107
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of N-acylated glycyl-(2-cyano) pyrrolidines were synthesized with the aim of generating structure-activity relationship (SAR) data for this class of compounds as inhibitors of fibroblast activation protein (FAP). Specifically, the influence of (1) the choice of the N-acyl group and (2) structural modification of the 2-cyanopyrrolidine residue were investigated. The inhibitors displayed inhibitory potency in the micromolar to nanomolar range and showed good to excellent selectivity with respect to the proline selective dipeptidyl peptidases (DPPs) DPP IV, DPP9 and DPP II. Additionally, selectivity for FAP with respect to prolyl oligopeptidase (PREP) is reported. Not unexpectedly, the latter data suggest significant overlap in the pharmacophoric features that define FAP or PREP-inhibitory activity and underscore the importance of systematically evaluating the FAP/PREP-selectivity index for inhibitors of either of these two enzymes. Finally, this study forwards several compounds that can serve as leads or prototypic structures for future FAP-selective-inhibitor discovery. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3412 / 3417
页数:6
相关论文
共 42 条
  • [1] PT-100, a small molecule dipeptidyl peptidase inhibitorg has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism
    Adams, S
    Miller, GT
    Jesson, MI
    Watanabe, T
    Jones, B
    Wallner, BP
    [J]. CANCER RESEARCH, 2004, 64 (15) : 5471 - 5480
  • [2] Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein α
    Aertgeerts, K
    Levin, I
    Shi, LH
    Snell, GP
    Jennings, A
    Prasad, GS
    Zhang, YM
    Kraus, ML
    Salakian, S
    Sridhar, V
    Wijnands, R
    Tennant, MG
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (20) : 19441 - 19444
  • [3] 2-cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV
    Ashworth, DM
    Atrash, B
    Baker, GR
    Baxter, AJ
    Jenkins, PD
    Jones, DM
    Szelke, M
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (10) : 1163 - 1166
  • [4] Pyrrolidides: Synthesis and structure-activity relationship as inhibitors of dipeptidyl peptidase IV
    Augustyns, KJL
    Lambeir, AM
    Borloo, M
    DeMeester, I
    Vedernikova, I
    Vanhoof, G
    Hendriks, D
    Scharpe, S
    Haemers, A
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1997, 32 (04) : 301 - 309
  • [5] Bachovchin W. W., 2007, U.S. Patent, Patent No. [PCT/US2006/026258, 2006026258]
  • [6] Search for substrates for prolyl oligopeptidase in porcine brain
    Brandt, I
    De Vriendt, K
    Devreese, B
    Van Beeumen, J
    Van Dongen, W
    Augustyns, K
    De Meester, I
    Scharpé, S
    Lambeir, AM
    [J]. PEPTIDES, 2005, 26 (12) : 2536 - 2546
  • [7] Suggested functions for prolyl oligopeptidase:: A puzzling paradox
    Brandt, Inger
    Scharpe, Simon
    Lambeir, Anne-Marie
    [J]. CLINICA CHIMICA ACTA, 2007, 377 (1-2) : 50 - 61
  • [8] Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata
    Brokopp, Chad E.
    Schoenauer, Roman
    Richards, Peter
    Bauer, Stefan
    Lohmann, Christine
    Emmert, Maximilian Y.
    Weber, Benedikt
    Winnik, Stephan
    Aikawa, Elena
    Graves, Kirk
    Genoni, Michele
    Vogt, Peter
    Luescher, Thomas F.
    Renner, Christoph
    Hoerstrup, Simon P.
    Matter, Christian M.
    [J]. EUROPEAN HEART JOURNAL, 2011, 32 (21) : 2713 - 2722
  • [9] Cheng JD, 2005, MOL CANCER THER, V4, P351
  • [10] Cheng JD, 2002, CANCER RES, V62, P4767